Bob Casey

The question I have is, what factors went into the conclusion that Daraprim was undervalued?

The incarnation of evil.

Nothing replaces or nothing can substitute for your own personal witness, and we appreciate you doing this.

Well, you should not have that uncertainty, especially in light of what you have already been through.

Pharmaceutical companies typically justify drug price increases... by expenditures such as research and development of the drug itself or a substitute...

Research demonstrates that direct investments in children can help close gaps in these important outcomes and can have lasting positive effects.

Sometimes it is you spend a buck on high-quality early learning and you get back multiples of that, sometimes into the teens.

Whenever a witness can bring a personal story, that makes a substantial impression on everyone here.

We appreciate that, because I know--I say this as a former State auditor general, where we would have audit findings and make a long series of recommendations, and you wonder if the State agency would be responsive.

Thank you, Mr. Chairman. Dr. King, welcome, and thank you for your testimony and your willingness to serve. We appreciate that commitment.

I think that word has acquired much more powerful meaning now as applied to these drugs.

I voted against the nominee for FDA Commissioner precisely because I think the FDA has failed in its mission.

Every State, every community has some metric or some horror story.

We face a continually evolving public health situation.

Senator Burr and I have worked together on public health preparedness issues for several years now.

I guess as a followup to that, what are the standards that you use to determine whether to require pediatric testing and labeling for medical countermeasures that would be used in children?

I hope that we can support the President's supplemental in a bipartisan way.

I am also a cosponsor of several pieces of legislation that would move us in the right direction.

I recently held a listening session with key addiction treatment stakeholders in New Jersey to address this growing crisis.

I applaud Senators Toomey and Portman for their leadership on this legislation, and I hope we can move it very soon.

I compliment Senator Portman for his work on that, and others with him.

A referral to a wait list, to me, is probably a pathway to heroin if that wait list is awfully long.

Deaths associated with opioids have quadrupled over the last 12 years to an astounding 78 deaths a day.

I appreciate the efforts that Chairman Hatch and Ranking Member Wyden have put into developing this legislation.

Access to cheap, highly potent heroin on the streets has become, by comparison, very cheap and easy.